View more on these topics

No cloning around

Many IFAs are steering clear of biotechnology funds, saying they are too risky for the average client. Recent biotech developments have seen the sector pushed into the spotlight but IFAs are warning that these funds are not for everyone and it is essential for clients to be fully informed.

Chase de Vere investment marketing manager Ian Millward says: “We are recommending biotech funds but only rarely. It would not be a standard recommendation, only for someone who wants something aggressive.

“The sector has potential but is a narrow market and we would want to ensure the client knew the situation. It is important not just to invest in something that has become the latest fashion but we would use them with caution.”

Fund managers say the market is extremely volatile and investment is highly speculative. The sector is seen as an area for long-term investment.

Hargreaves Lansdown chief executive Peter Hargreaves suggests biotech funds are not something to recommend as a mainline investment.

He says: “Biotechnology is something that you buy as an adjunct to a portfolio. It is the spice round the side of a fairly full portfolio. If a client wants something exciting then these are the funds we would explore. But biotechnology is an area that is very specific and is only for the man who has everything.”

Much of the recent boom in this area is down to the completion of the sequencing and mapping of the human genome, allowing life science companies the opportunity to produce new types of medicine at a unprecedented rate.

Rothschild Asset Management head of bio science unit Edward Wawrzynczak says: “The dev-elopment of new medicines is a long process but we have seen the arrival of lots of new viable biotechnology companies, proving this is an industry that is not going to disappear overnight.

“We are confident the industry is going to be a driving force over the next 10 years. It is now recognised this is an important sector. It has been possible for fund managers to ignore it but they cannot afford to do that now.”

This year has seen the launch of several funds with a biotech focus. People are seeing the benefit of manufacturing new drugs and money is increasingly coming into this area. Fund managers see the potential of this activity as a significant investment opportunity.

Gartmore techtornado fund manager Tim Dainton says: “The completion of the genome sequence has brought euphoria on stockmarkets. Some of these companies still may come to nothing but there is an appetite for the next deal to come along and the market is showing immense opportunity.”

The sector&#39s volatility has led to fund managers investing in the area with a lot of caution. Many of the funds are underweight in biotech.

But the recent uplift in the market is pushing managers to start putting more emphasis on this area. Framlington marketing manager Lesley Hankin says the biotech part of its health fund has been built up since the end of last year from 40 per cent to 55 per cent in February.

She says: “We have recently cut back as some of the biotechnology companies are looking overvalued but I do not think the sector as a whole is overvalued. There is a lot of activity there and demand is picking up. We have not cut back completely as we still have 50 per cent in there.”

Recommended

… but fund manager still scoops Man Wing

Despite the week&#39s departures, Chase Fleming managed to make a key personnel acquisition of its own this week, as it poached HSBC&#39s chief investment officer for Asian equities excluding Japan.Chung Man Wing (pictured right), who managed the Hong Kong growth fund at HSBC, will head Fleming&#39s Greater China team from October.Man Wing will be replaced […]

LIA relaunches with the aim of uniting advisers

The LIA has restated its aim to unite financial advisers under a single professional body as it announces a new name and strategies.In future, the LIA will be known by the initials LIA rather than by the full title Life Insurance Association, as revealed in Money Marketing last month.Speaking at the launch of the new […]

Pension fears over transfer transparency

The FSA should force life offices to disclose expenses deducted from with-profits funds&#39 terminal bonuses under RU64, according to some pension experts.The call comes amid fears that charges on with-profits pensions will not be transparent in comparison with charges on unit-linked invested schemes transferring to stakeholder contracts.It is claimed this makesit impossible to work out […]

Baillie Gifford boosts weighting in Japan

Fund manager Baillie Gifford is boosting its weighting in Japanese stocks across its range of investments in response to the solid economic prospects in the Far East.The latest market report from the company says the region continues its steady recovery from the Asian flu of the early 1990s. Although there is still a large degree […]

Newsletter

News and expert analysis straight to your inbox

Sign up

Comments

    Leave a comment

    Close

    Why register with Money Marketing ?

    Providing trusted insight for professional advisers.  Since 1985 Money Marketing has helped promote and analyse the financial adviser community in the UK and continues to be the trusted industry brand for independent insight and advice.

    News & analysis delivered directly to your inbox
    Register today to receive our range of news alerts including daily and weekly briefings

    Money Marketing Events
    Be the first to hear about our industry leading conferences, awards, roundtables and more.

    Research and insight
    Take part in and see the results of Money Marketing's flagship investigations into industry trends.

    Have your say
    Only registered users can post comments. As the voice of the adviser community, our content generates robust debate. Sign up today and make your voice heard.

    Register now

    Having problems?

    Contact us on +44 (0)20 7292 3712

    Lines are open Monday to Friday 9:00am -5.00pm

    Email: customerservices@moneymarketing.com